INS and type 2 diabetes mellitus: Among hypoglycemic oral drugs, gliclazide as a second-generation sulfonylurea augments the ability to secrete insulin from pancreatic β-cells in the treatment of T2D [3], but a major side effect in using gliclazide is weight gain [4].